Semaglutide preferentially reduces visceral fat and improves body composition beyond the scale | Research

The takeaway

Semaglutide reduces total fat by 3.5% and visceral fat by 2.0% while increasing lean body mass proportion by 3.0%, improves HbA1c by 1.2-1.8%, uniquely lowers LDL/total cholesterol among GLP-1 drugs, and slows weight regain after bariatric surgery.

Visceral fat down, lean mass up
Semaglutide preferentially targets dangerous visceral fat (-2%) while increasing lean mass proportion (+3%), producing metabolically superior weight loss

What the researchers found

Fat mass: -3.5% total, -2.0% visceral. Lean mass: +3.0% proportion. HbA1c: -1.2-1.8%. LDL: -0.16 mmol/L, total cholesterol: -0.48 mmol/L (unique among GLP-1RAs). Reduced hunger, increased satiety. Weight regain on discontinuation.

Why it matters

Scale weight does not capture the full picture. Semaglutide's preferential fat reduction (especially visceral) with lean mass preservation addresses the "quality" of weight loss—more important for metabolic health than total kilograms lost.

How the study worked

Narrative review of clinical trial data on semaglutide body composition, glycemic, lipid, appetite, and weight maintenance effects.

What this study cannot tell us

Narrative review. Body composition data from limited studies. Lean mass preservation may partly reflect proportional change, not absolute preservation.

How to read the evidence

Narrative review of clinical trial body composition and metabolic data.

When this study was published

Published in 2025.

The bigger picture

This review reframes semaglutide from a "weight loss drug" to a comprehensive metabolic remodeling agent that improves body composition, lipids, glucose, and appetite through multiple mechanisms.

Questions still open

Does semaglutide truly preserve absolute lean mass or just change proportions?
Can exercise further enhance semaglutide's body composition effects?
Why is semaglutide unique in reducing LDL among GLP-1 drugs?

Common questions

Does semaglutide cause muscle loss?

The data suggest semaglutide preferentially reduces fat—especially dangerous visceral fat—while the proportion of lean body mass actually increases. This means the weight you lose is primarily fat, not muscle. However, maintaining adequate protein intake and exercise is still recommended.

What happens when you stop semaglutide?

Weight regain occurs after stopping semaglutide, which is consistent with obesity being a chronic disease requiring ongoing management. Continued treatment sustains further weight loss. Semaglutide can also slow weight regain after bariatric surgery.

Read the original research

Exploring beyond numeric weight loss: The metabolic effects of semaglutide.

Clinical nutrition ESPEN, 67, 435-440

View on PubMed ↗Publisher’s paper ↗

Citation

Sokary, Sara; Bawadi, Hiba. (2025). Exploring beyond numeric weight loss: The metabolic effects of semaglutide.. Clinical nutrition ESPEN, 67, 435-440. https://doi.org/10.1016/j.clnesp.2025.03.010